Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD

Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD

Business Wire

Published

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, has entered into a licensing agreement with Braingaze Ltd. (Braingaze) and launched its new business, Tris Digital Health, which will focus on the development and commercialization of digital diagnostic and therapeutic products for neurological health conditions. Tris has secured e

Full Article